ArticleEuropean radiology2023
Association of computed tomography-based body composition with survival in metastatic renal cancer patient received immunotherapy: a multicenter, retrospective study.
Article in European radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Before-treatment body mass index as a prognostic factor in cancer patients receiving immune checkpoint inhibitors: a systematic review and dose-response meta-analysis.Frontiers in immunology · 2026Pooled it
- Prognostic value of body adipose tissue parameters in cancer patients treated with immune checkpoint inhibitors.Frontiers in immunology · 2025Pooled it
- Imaging-based adipose biomarkers for predicting clinical outcomes of cancer patients treated with immune checkpoint inhibitors: a systematic review.Frontiers in oncology · 2023Pooled it
- Cancer Cachexia in Advanced Renal Cell Carcinoma: From Molecular Mechanisms to Prognostic Assessment.International journal of molecular sciences · 2026Review
- Prognostic value of CT-derived body composition phenotypes for patients undergoing resection of hepatocellular carcinoma: a multicenter study.Abdominal radiology (New York) · 2026Article
- Body composition and renal cell carcinoma prognosis in elderly patients: a retrospective cohort study.BMC urology · 2026Article
- A nomogram model based on CT-assessed body composition parameters for predicting postoperative recurrence in advanced gastric cancer.Abdominal radiology (New York) · 2026Article
- A personalized prognostic model based on preoperative body composition and nutritional parameters for gastric cancer patients receiving neoadjuvant chemotherapy.Frontiers in immunology · 2026Article
- Intravenous contrast medium impairs CT-based muscle quality but not quantity assessment: a translational study.Frontiers in radiology · 2026Article
- Host-related Determinants of Response to Immunotherapy in Non-small Cell Lung Cancer: The Interplay of Body Composition, Metabolism, Sex and Immune Regulation.Current oncology reports · 2025Review
- CT-based body composition and inflammatory nutritional biomarker nomogram for predicting early postoperative recurrence of non-small cell lung cancer: a multicenter study.Journal of thoracic disease · 2025Article
- The prognostic value of sarcopenia and sarcopenic obesity in patients with lung cancer receiving immunotherapy: a propensity score matching study.The oncologist · 2025Article
- Article
- Immunometabolism in cancer: a systemic perspective.Frontiers in immunology · 2025Review
- Perioperative evaluation of CT-based body composition as predictors of postoperative outcome following pancreaticoduodenectomy.Frontiers in nutrition · 2025Article
- Impact of body composition on pathological response to neoadjuvant immunotherapy in dMMR/MSI-H colorectal cancer.Frontiers in immunology · 2025Article
- Clinicopathological characteristics correlated with programmed cell death-ligand 1 expression in advanced lung adenocarcinoma.Journal of thoracic disease · 2023Article
- Body composition predicts prognosis of hepatocellular carcinoma patients undergoing immune checkpoint inhibitors.Journal of cancer research and clinical oncology · 2023Article
- Gut microbiome and nutrition-related predictors of response to immunotherapy in cancer: making sense of the puzzle.BJC reports · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 6 institutions in 1 country.
Funding
Abstract
objectivesTo investigate the association of computed tomography-assessed body composition with survival outcomes of metastatic renal cell carcinoma (mRCC) received immunotherapy.
methodsIn this multicenter, retrospective study, we reviewed 251 mRCC patients who received anti-PD1 from five centers. We analyzed the relationship between BMI, skeletal muscle area (SM), subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), and subcutaneous adipose percentage (SAT%) with progression-free survival (PFS) and overall survival (OS). The spatial localization T cells was investigated by multiplex immunofluorescence.
resultsAmong 224 evaluable patients, 23 (10.3%) patients were underweight, 118 (52.7%) had normal weight, 65 (29%) were overweight, and 18 patients (8%) were obese. The median age was 55 years and most patients were male (71%). No significant improvement in PFS (HR, 0.61; 95% CI, 0.27-1.42) or OS (HR, 1.09; 95% CI, 0.38-3.13) was observed for the obese patients. Besides, SM, VAT, and SAT were not associated with survival outcomes (all p > 0.05). Interestingly, SAT% independently predicted PFS (as continuous variable, HR: 0.02; 95% CI, 0.01-0.11) and OS (HR:0.05; 95% CI, 0.01-0.39), which remained significant in multivariate modeling (as continuous variable, adjusted HR for PFS, 0.01; 95% CI, 0.00-0.04; adjusted HR for OS, 0.08; 95% CI, 0.01-0.72). These associations were consistent in subgroup analysis of different gender, BMI, PD-L1 positive, and sarcopenia group. Tumor of high SAT% patients had a higher intratumoral PD1
conclusionHigh SAT% predicts better outcomes in mRCC patients treated with anti-PD1 and T cell location may account for the better response. KEY POINTS: • CT-based subcutaneous adipose percentage independently predicted progression-free survival and overall survival. • Patients with a higher subcutaneous adipose percentage had a higher intratumoral PD1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.